Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72834 record(s)

Req # A-2024-000179

Adverse Drug Reaction (ADR). Report number: E2B_06642692.

Organization: Health Canada

120 page(s)
August 2024

Req # A-2024-000185

Adverse Drug Reactions (ADRs). Report numbers: 001054745, 001076705.

Organization: Health Canada

7 page(s)
August 2024

Req # A-2024-000226

Adverse Drug Reactions (ADRs). Report numbers: 001081973, 001084219.

Organization: Health Canada

7 page(s)
August 2024

Req # A-2024-000227

Adverse Drug Reaction (ADR) for FAMCICLOVIR. Report number: E2B_07048452. ADR for ASAPHEN. Report number: 1077952. ADR for STOOL SOFTENER. Report number: E2B_07041973. ADR for RIVAROXABAN. Report number: 1077634.

Organization: Health Canada

55 page(s)
August 2024

Req # A-2024-000230

Adverse Drug Reactions (ADRs) for Dexilant. Report numbers: E2B_07047378, 001083404, 001083459, 001084337. ADRs for Ondansetron. Report numbers: E2B_07036937, E2B_07038477, E2B_07018563, E2B_07016780, 001083684.

Organization: Health Canada

567 page(s)
August 2024

Req # A-2024-000233

Adverse Drug Reactions (ADRs) for MEZAVANT. Report numbers: E2B_07024875, E2B_07024287, 001082743, E2B_07030498. ADRs for Mesalazine. Report numbers: E2B_07024290, E2B_07044749, E2B_07005577, E2B_07034218, E2B_07019303.

Organization: Health Canada

186 page(s)
August 2024

Req # A-2024-000234

Adverse Drug Reactions (ADRs) for VYVANSE. Report numbers: 001078818, 001084076, E2B_06993638. ADRs for C1 Esterase Inhibitor (Human). Report numbers: E2B_07053195, E2B_07025538, E2B_07017197. ADRs for GAMMAGARD LIQUID. Report numbers: 001080211,…

Organization: Health Canada

143 page(s)
August 2024

Req # A-2024-000242

Adverse Drug Reactions (ADRs). Report numbers: 001080559, 001078726, 001083827, 001080806, E2B_07049389, E2B_07047263, 001083763, 001077257, 001078054, E2B_07047631.

Organization: Health Canada

407 page(s)
August 2024

Req # A-2024-000250

Adverse Drug Reactions (ADRs). Report numbers: E2B_06980230, E2B_04724876, E2B_07005158, 001074116, 001079471, 001077365, 001083606.

Organization: Health Canada

196 page(s)
August 2024

Req # A-2024-000274

Adverse Drug Reactions (ADRs). Report numbers: E2B_07039945, E2B_07040159, E2B_07040430, E2B_07041494, E2B_07041838.

Organization: Health Canada

35 page(s)
August 2024
Date modified: